Stem cell transplantation: a 10-year single.centre experience
Journal
Bone Marrow Transplantation Journal 46(Suppl 1): S90–S389
Date Issued
2011
Author(s)
Ivanovski, Martin
DOI
10.1038/bmt.2011.48
Abstract
Stem cell transplantation is the treatment of choice for patients
with hematological malignant diseases. Aim of this study is to
evaluate the results in 10 years experience with this procedure
in our center. During a this period we have treated 195
patients with different malignant hematological diseases.107
male, 88 female with median age of 34 years. Allogeneic
sibling transplantation were performed in 56 patients, and
autologous transplantation in 139 patients. According to
diagnose: AML:91 ALL:10 CML:7 CLL:1 MP:1 NHL:20 HD:27
MM:34 AA:2 Ewing sarcoma: 1. Bone marrow was used as
a source of stem cells in 28, PBSC in 168 patients. Conditioning
regimen consisted chemotherapy with: Bu-Cy2,Bu-
Cy-Mel,BEAM, high dose Melphalan, high dose ICE,Flu/Mel.
Engraftment was reached on day +12 (10-24). Median value
of MNC in BMT was 3,8x10/Kg (2,5-4,5), while in PBSCT
MNC was 4,1x10 (2,8-12,0). TRM in allogeneic recipients
was 16%, with non-relapse mortality 10%, and in autologous
recipients TRM was 3,8% with non-relapse mortality 2,0%.
Primary disease was cause of death after transplantation in
40% in allogeneic, and 66% in autologous transplantation.
35% of allogeneic and 28% of autologous transplantation
were transplanted in active disease.
with hematological malignant diseases. Aim of this study is to
evaluate the results in 10 years experience with this procedure
in our center. During a this period we have treated 195
patients with different malignant hematological diseases.107
male, 88 female with median age of 34 years. Allogeneic
sibling transplantation were performed in 56 patients, and
autologous transplantation in 139 patients. According to
diagnose: AML:91 ALL:10 CML:7 CLL:1 MP:1 NHL:20 HD:27
MM:34 AA:2 Ewing sarcoma: 1. Bone marrow was used as
a source of stem cells in 28, PBSC in 168 patients. Conditioning
regimen consisted chemotherapy with: Bu-Cy2,Bu-
Cy-Mel,BEAM, high dose Melphalan, high dose ICE,Flu/Mel.
Engraftment was reached on day +12 (10-24). Median value
of MNC in BMT was 3,8x10/Kg (2,5-4,5), while in PBSCT
MNC was 4,1x10 (2,8-12,0). TRM in allogeneic recipients
was 16%, with non-relapse mortality 10%, and in autologous
recipients TRM was 3,8% with non-relapse mortality 2,0%.
Primary disease was cause of death after transplantation in
40% in allogeneic, and 66% in autologous transplantation.
35% of allogeneic and 28% of autologous transplantation
were transplanted in active disease.
File(s)![Thumbnail Image]()
Loading...
Name
Stem cell transplantation a 10-year single centre.pdf
Size
284.29 KB
Format
Adobe PDF
Checksum
(MD5):b2a4868867f0f27debb0a16cd7de0688